# Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

> **NCT04910152** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hannah Choe, MD** · enrollment: 2 (actual)

## Conditions studied

- Acute Graft Versus Host Disease
- Steroid Refractory Graft Versus Host Disease

## Interventions

- **DRUG:** BRD4 Inhibitor PLX51107

## Key facts

- **NCT ID:** NCT04910152
- **Lead sponsor:** Hannah Choe, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-19
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910152, "Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04910152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*